Histone Deacetylase Inhibitors as Anticancer Drugs
Open accessThe DOI matches its Crossref record; 181 of the 184 references it cites were found in a registry or an index.
Abstract
Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT). HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response. Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc. HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy. HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma. Other HDAC inhibitors are in clinical trials for the treatment of hematological and solid malignancies. The results of such studies are promising but further larger studies are needed. Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance. Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclinical and clinical studies, including the combination with other therapeutic modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HDAC inhibitors have been considered for usage in combinatorial therapies for several cancers including melanoma47,65–67.”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They work as anticancer drugs by inducing cell cycle arrest, differentiation, and cell death, and by reducing angiogenesis and modulating the immune response; however, the mechanisms of their effects can differ depending on the individual HDAC inhibitor and its dose and on the type of cancer [164].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [164]
In the citing paper
“HDAC inhibitors act as antitumoral agents by antagonizing the pro-transcriptional effects of histone deacetylation and silencing the expression of oncogenic factors through chromatin remodeling43.”
From Causal identification of single-cell experimental perturbation effects with CINEMA-OT (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Dasmahapatra, G., Lembersky, D., Kramer, L., Fisher, R. I., Friedberg, J., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 105 · cited 2×
“SAHA carfilzomib in vitro and nude mice xenografts, lymphoma cell SUDHL16, SUDHL4 , SUDHL6, OCI-LY10, OCI-LY3 bortezomib-resistant SUDHL16-10BR, OCI-LY10-40BR and lymphoma cells frompatients Potentiation [152]”
BackgroundRetractedDasmahapatra, G., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 57 · cited 2×
“SNDX-275, SAHA carfilzomib, bortezomib in vitro and nude mice xenografts, lymphoma cell Granta 519, Rec-1, HF-4B, JVM-2, MINO, JVM-13 Potentiation [153]”
BackgroundRetractedBalliu, M., Guandalini, L., Romanelli, M. N., D’Amico, M., & Paoletti, F. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12345 · Cited by 31 · cited 3×
“Moreover, inhibition of HDAC6 activates naïve T cells [119,120].”
BackgroundRetractedThe Wnt Signaling Pathway in Development and Disease
Logan, C. Y., & Nusse, R. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.113126 · Cited by 5,325 · cited 1×
“The Wnt signaling pathway plays an important role in various cancers such as colon, breast, ovarian, prostate and endometrial cancers as well as medulloblastoma and melanoma [103].”
BackgroundMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“Several tumor associated antigens have been shown to be epigenetically silenced in malignancies impede immune recognition by cytotoxic T cells and contributing to worse prognosis [124,125].”
BackgroundActivation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239 · cited 14×
“We found that VPA and TSA change CYP enzyme expression in neuroblastoma cells [135].”
BackgroundInfluentialCancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203 · cited 2×
“Therefore, HDACs may be essential for the maintenance of a set of key genes required for survival and growth of cancer cells but not of normal ones [38].”
BackgroundAnticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“HATs catalyze the transfer of an acetyl group from acetyl-CoA to the ε-NH2 group of lysine residues in proteins, while HDACs remove it [12].”
BackgroundRegulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D., Gratton, J.-P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,608 · cited 1×
“eNOS, Akt in vitro endothelial cells, Akt transfected, mutatnteNOS / [110]”
BackgroundActivation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
Haberland, M., Montgomery, R. L., & Olson, E. N. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2485 · Cited by 2,526 · cited 1×
“prenatally with severe proliferation defects and general growth retardation; HDAC2-null mice die the first day after birth for cardiac malformations; and HDAC3-null mice die prenatally for defects in gastrulation [3,4].”
BackgroundHistone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors
Finnin, M. S., Donigian, J. R., Cohen, A., Richon, V. M., Rifkind, R. A., Marks, P. A., Breslow, R., & Pavletich, N. P. (1999) · Nature · doi:10.1038/43710 · Cited by 1,714 · cited 1×
“The Zn2+ ion stabilizes the acetylated substrate in the catalytic center of the enzyme and polarizes the carbonyl group making the carbon to be a better target for nucleophilic water molecules [21].”
BackgroundThe functional role of long non-coding RNA in human carcinomas
Gibb, E. A., Brown, C. J., & Lam, W. L. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-38 · Cited by 1,619 · cited 1×
“Intergenic lncRNAs regulate gene expression through modifying the chromatin complexes or RNA binding proteins and their aberrant expression is associated with cancer [96].”
BackgroundHistone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy
Lee, I. H., Cao, L., Mostoslavsky, R., Lombard, D. B., Liu, J., Bruns, N. E., Tsokos, M., Alt, F. W., & Finkel, T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712145105 · Cited by 1,476 · cited 2×
“SIRT1 forms a complex with components of the autophagy machinery (Atg5, -7, and -8) and stimulates autophagy [78].”
BackgroundNew and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men
Yang, X.-J., & Seto, E. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2346 · Cited by 1,230 · cited 1×
“prenatally with severe proliferation defects and general growth retardation; HDAC2-null mice die the first day after birth for cardiac malformations; and HDAC3-null mice die prenatally for defects in gastrulation [3,4].”
BackgroundDuvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141 · cited 1×
“Administration of SAHA in refractory CTCL patients showed in phase II trials objective response in nearly 30% [166,167].”
BackgroundRichon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090 · cited 4×
“Its product blocks the formation of dimers from cyclins and cyclin dependent kinases (CDKs) that induce cell cycle arrest and inhibition of cell differentiation [43,44].”
BackgroundInfluentialHistone acetyltransferase complexes: one size doesn't fit all
Lee, K. K., & Workman, J. L. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2145 · Cited by 1,087 · cited 1×
“However, they do not contain true consensus HAT domains and therefore represent an “orphan class” of HAT enzymes [26].”
BackgroundOlsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,055 · cited 1×
“Administration of SAHA in refractory CTCL patients showed in phase II trials objective response in nearly 30% [166,167].”
BackgroundCausal Relationship between the Loss of RUNX3 Expression and Gastric Cancer
Li, Q.-L., Ito, K., Sakakura, C., Fukamachi, H., Inoue, K.-I., Chi, X.-Z., Lee, K.-Y., Nomura, S., Lee, C.-W., Han, S.-B., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)00690-6 · Cited by 1,028
Lysine Acetylation: Codified Crosstalk with Other Posttranslational Modifications
Yang, X.-J., & Seto, E. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.07.002 · Cited by 1,006 · cited 1×
“Most of the classic HDACs form large complexes with multiple transcriptional co-repressors (such as Sin3 (Transcriptional regulatory protein SIN3), NuRD (Nucleosome remodeling and deacetylase complex), NcoR (Nuclear receptor co-repressor) and SMRT (Silencing mediator of retinoic acid and thyroid hormone receptors) wit…”
BackgroundAcetylation Is Indispensable for p53 Activation
Tang, Y., Zhao, W., Chen, Y., Zhao, Y., & Gu, W. (2008) · Cell · doi:10.1016/j.cell.2008.03.025 · Cited by 838 · cited 3×
“Moreover, the p53 protein interactions with its activators ASPPs (Ankyrin-repeat-, SH3-domain- and proline-rich region containing proteins), 53BP1 (p53-binding protein), TiP60/hMOF (Human males absent on the first), hCAS/CSE1L (Cellular apoptosis susceptibility protein), and HZF (Hematopoietic zinc finger) are regulat…”
BackgroundInfluential(2002) · PubMed · Cited by 732
Regulation and Destabilization of HIF-1α by ARD1-Mediated Acetylation
Jeong, J.-W., Bae, M.-K., Ahn, M.-Y., Kim, S.-H., Sohn, T.-K., Bae, M.-H., Yoo, M.-A., Song, E. J., Lee, K.-J., & Kim, K.-W. (2002) · Cell · doi:10.1016/s0092-8674(02)01085-1 · Cited by 716
Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility
Montgomery, R. L., Davis, C. A., Potthoff, M. J., Haberland, M., Fielitz, J., Qi, X., Hill, J. A., Richardson, J. A., & Olson, E. N. (2007) · Genes & Development · doi:10.1101/gad.1563807 · Cited by 712 · cited 1×
“ACNA2D2 HDAC1 or HDAC2 mutated C57BL/6 mice / [107]”
Acetylation of non-histone proteins modulates cellular signalling at multiple levels
Spange, S., Wagner, T., Heinzel, T., & Krämer, O. H. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.08.027 · Cited by 664 · cited 1×
“, mRNA splicing, transport and integrity; translation; activity, localization, stability and protein interactions [18].”
BackgroundEmerging functional and mechanistic paradigms of mammalian long non-coding RNAs
Moran, V. A., Perera, R. J., & Khalil, A. M. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks296 · Cited by 637 · cited 1×
“They also have epigenetic effects and are precursors of miRNAs [93].”
BackgroundBoth corepressor proteins SMRT and N‐CoR exist in large protein complexes containing HDAC3
Li, J., Wang, J., Wang, J., Nawaz, Z., Liu, J. M., Qin, J., & Wong, J. (2000) · The EMBO Journal · doi:10.1093/emboj/19.16.4342 · Cited by 629 · cited 1×
“HDAC complexes can contribute to gene repression through two mechanisms—specific targeting by repressors and the constitutive association with chromatin [24,25].”
BackgroundTumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells
Nebbioso, A., Clarke, N., Voltz, E., Germain, E., Ambrosino, C., Bontempo, P., Alvarez, R., Schiavone, E. M., Ferrara, F., Bresciani, F., et al. (2005) · Nature Medicine · doi:10.1038/nm1161 · Cited by 610 · cited 2×
“death receptor in vitro AML cells from patients, normal CD34+ progenitors MS275 [61]”
BackgroundWilson, A. J., Byun, D.-S., Popova, N., Murray, L. B., L'Italien, K., Sowa, Y., Arango, D., Velcich, A., Augenlicht, L. H., & Mariadason, J. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510023200 · Cited by 575 · cited 1×
“In addition, HDAC3 is overexpressed in colon and breast tumors [11], whereas HDAC6 is highly expressed in mammary tumors, HDAC8 is overexpressed in neuroblastoma cells and HDAC11 mainly in rhabdomyosarcoma [12–14].”
Background(2011) · PubMed Central · Cited by 560
Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA.
Kim, M. S., Blake, M., Baek, J. H., Kohlhagen, G., Pommier, Y. G., & Carrier, F. (2003) · PubMed · Cited by 529
Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis
Zhu, P., Martin, E., Mengwasser, J., Schlag, P., Janssen, K.-P., & Göttlicher, M. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00114-x · Cited by 525 · cited 5×
“Moreover, HDAC inhibitors decrease polyp generation in a colon carcinoma model of APC deficient mice, probably via damage of the HDAC2 by degradation in proteasomes [10].”
BackgroundInfluentialThe histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2
Krämer, O. H., Zhu, P., Ostendorff, H. P., Golebiewski, M., Tiefenbach, J., Peters, M. A., Brill, B., Groner, B., Bach, I., Heinzel, T., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg315 · Cited by 523 · cited 14×
“We found that VPA and TSA change CYP enzyme expression in neuroblastoma cells [135].”
BackgroundInfluentialInsinga, A., Monestiroli, S., Ronzoni, S., Gelmetti, V., Marchesi, F., Viale, A., Altucci, L., Nervi, C., Minucci, S., & Pelicci, P. G. (2005) · Nature Medicine · doi:10.1038/nm1160 · Cited by 516 · cited 1×
“In vivo experiments with xenograft using tumor cells with TRAIL and Fas suppressed by siRNA showed a significant decrease in apoptosis after treatment with VPA [62].”
MethodButler, L. M., Zhou, X., Xu, W.-S., Scher, H. I., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182372299 · Cited by 510 · cited 2×
“SAHA and entinostat increase expression of binding protein-2 (TBP-2) that inhibits thioredoxin in LNCaP prostate cancer, T24 bladder cancer and MCF7 breast cancer cells [68].”
BackgroundUpregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer
Halkidou, K., Gaughan, L., Cook, S., Leung, H. Y., Neal, D. E., & Robson, C. N. (2004) · The Prostate · doi:10.1002/pros.20022 · Cited by 509
Ruefli, A. A., Ausserlechner, M. J., Bernhard, D., Sutton, V. R., Tainton, K. M., Kofler, R., Smyth, M. J., & Johnstone, R. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191208598 · Cited by 488 · cited 9×
“Besides, these effects on gene expression, the HDAC inhibitors increase amounts of reactive oxygen species (ROS) that can induce apoptosis in leukemic cells (Jurkat, ML-1, U937, HL-60, K-562, CEM-CCRF and its doxorubicin selected P-glycoprotein overexpressing subline and FDC-P1 and sublines overexpressing Bid, Bcl-2 a…”
BackgroundInfluentialProspects: Histone deacetylase inhibitors
Dokmanovic, M., & Marks, P. A. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20532 · Cited by 479
(2003) · PubMed · Cited by 465
Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W. G., Faderl, S., Koller, C., Morris, G., Rosner, G., et al. (2008) · Blood · doi:10.1182/blood-2007-06-098061 · Cited by 459 · cited 2×
“Phase I study of patients with advanced leukemia and MDS treated with SAHA showed clinical benefit in AML and MDS [169].”
BackgroundSirtuins — novel therapeutic targets to treat age-associated diseases
Lavu, S., Boss, O., Elliott, P. J., & Lambert, P. D. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2665 · Cited by 426 · cited 1×
“They might act against different types of neurodegenerations and cancers [30].”
BackgroundMariadason, J. M., Corner, G. A., & Augenlicht, L. H. (2000) · PubMed · Cited by 415
Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy
Cao, D. J., Wang, Z. V., Battiprolu, P. K., Jiang, N., Morales, C. R., Kong, Y., Rothermel, B. A., Gillette, T. G., & Hill, J. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015081108 · Cited by 405 · cited 14×
“We found that VPA and TSA change CYP enzyme expression in neuroblastoma cells [135].”
BackgroundInfluentialTargeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.3 · Cited by 404 · cited 1×
“Despite the promising results in the treatment of CTCL, SAHA and romidepsin have not been effective in studies with different solid tumors (neuroendocrine tumors, glioblastoma multiforme, mesothelioma, refractory breast, colorectal, NSCLC, prostate, head and neck, renal cell, ovarian, cervical and thyroid cancers) and…”
ResultO'Connor, O. A., Heaney, M. L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Curly, T., Moskowitz, C., Portlock, C., Horwitz, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9679 · Cited by 404 · cited 1×
“Despite the promising results in the treatment of CTCL, SAHA and romidepsin have not been effective in studies with different solid tumors (neuroendocrine tumors, glioblastoma multiforme, mesothelioma, refractory breast, colorectal, NSCLC, prostate, head and neck, renal cell, ovarian, cervical and thyroid cancers) and…”
ResultDeroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.-M., Nusgens, B. V., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205108 · Cited by 400 · cited 3×
“In addition, HDAC inhibitors decrease the levels of the VEGF receptors in neuroblastoma cells [113].”
BackgroundHistone deacetylase 8 in neuroblastoma tumorigenesis
Oehme, I., Deubzer, H. E., Wegener, D., Pickert, D., Linke, J.-P., Hero, B., Kopp-Schneider, A., Westermann, F., Ulrich, S. M., von Deimling, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0684 · Cited by 398
miR-449a targets HDAC-1 and induces growth arrest in prostate cancer
Noonan, E. J., Place, R. F., Pookot, D., Basak, S., Whitson, J. M., Hirata, H., Giardina, C., & Dahiya, R. (2009) · Oncogene · doi:10.1038/onc.2009.19 · Cited by 396 · cited 2×
“, miR-449a regulates prostate cancer both androgen dependent and independent cells (PC-3, DU-145, BHP-1 and LNCaP) growth and viability by targeting and repressing HDAC1 [92].”
BackgroundMunster, P. N., Thurn, K. T., Thomas, S., Raha, P., Lacevic, M., Miller, A., Melisko, M., Ismail-Khan, R., Rugo, H., Moasser, M., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.156 · Cited by 391 · cited 1×
“SAHA improved effect of carboplatin and paclitaxel in NSCLC [178] and reversed resistance to tamoxifen in estrogen receptor positive breast cancer [179].”
BackgroundPei, X.-Y., Dai, Y., & Grant, S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0561 · Cited by 382 · cited 2×
“Treatment of multiple myeloma cells with bortezomib made the cells more sensitive to HDAC inhibitors [150].”
BackgroundEpigenetic Therapeutics: A New Weapon in the War Against Cancer
Ahuja, N., Sharma, A. R., & Baylin, S. B. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-111314-035900 · Cited by 363 · cited 1×
“Clinical trial with the combination of the immune checkpoint therapy with the HDAC inhibitor is ongoing [181].”
BackgroundMaintenance of cardiac energy metabolism by histone deacetylase 3 in mice
Montgomery, R. L., Potthoff, M. J., Haberland, M., Qi, X., Matsuzaki, S., Humphries, K. M., Richardson, J. A., Bassel-Duby, R., & Olson, E. N. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35847 · Cited by 362 · cited 1×
“PPAR, ERR HDAC3 conditional C57BL/6 mice / [108]”
Increased expression of histone deacetylase 2 is found in human gastric cancer
SONG, J., NOH, J. H., LEE, J. H., EUN, J. W., AHN, Y. M., KIM, S. Y., LEE, S. H., PARK, W. S., YOO, N. J., LEE, J. Y., et al. (2005) · APMIS · doi:10.1111/j.1600-0463.2005.apm_04.x · Cited by 346 · cited 1×
“High levels of HDAC2 were found in colorectal, cervical and gastric cancers [9,10].”
BackgroundExpression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues
Choi, J., Kwon, H. J., Yoon, B., Kim, J., Han, S. U., Joo, H. J., & Kim, D. (2001) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.2001.tb02153.x · Cited by 346
Expression profile of class I histone deacetylases in human cancer tissues
Nakagawa, M., Oda, Y., Eguchi, T., Aishima, S.-I., Yao, T., Hosoi, F., Basaki, Y., Ono, M., Kuwano, M., Tanaka, M., et al. (2007) · Oncology Reports · doi:10.3892/or.18.4.769 · Cited by 341
The thioredoxin-thioredoxin reductase system: over-expression in human cancer.
Lincoln, D. T., Emadi, E. M. A., Tonissen, K. F., & Clarke, F. M. (2003) · PubMed · Cited by 337
Yuan, P.-X., Huang, L.-D., Jiang, Y.-M., Gutkind, J. S., Manji, H. K., & Chen, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104309200 · Cited by 332 · cited 9×
“Although it is not yet clear how HDAC inhibitors affect ERK, it is supposed that they can induce synthesis of a still unknown factor that activate the ERK signaling pathway [65] or is incorporated into phospholipid molecules that activates ERK via the phosphatidylinositol 3-kinase (PI-3K)/Janus kinase 2 (JAK 2)/MEK-1-…”
BackgroundInfluentialHull, E. E., Montgomery, M. R., & Leyva, K. J. (2016) · BioMed Research International · doi:10.1155/2016/8797206 · Cited by 313 · cited 2×
“In various cancer cells, the shift to an increased acetylation/deacetylation ratio by HDAC inhibition was found to have a substantial effect on their fate (for overview see [19]).”
BackgroundGiles, F., Fischer, T., Cortes, J., Garcia-Manero, G., Beck, J., Ravandi, F., Masson, E., Rae, P., Laird, G., Sharma, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0511 · Cited by 312 · cited 1×
“Panobinostat underwent phase I and II clinical studies for the treatment of both solid and hematologic malignancies and phase III clinical trials for CTCL and chronic myeloid leukemia that showed promising results against CTCL [172] and leukemias, respectively, and proved the increased acetylation of histones in malig…”
BackgroundQuantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast*
Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Ando, Y., Mita, K., Hamaguchi, M., Hara, Y., Kobayashi, S., & Iwase, H. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-6001-1 · Cited by 305
Sandor, V, Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M. V., & Bates, S. E. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1327 · Cited by 290 · cited 5×
“CDKN1A/p21 in vitro normal breast MCF-10A, prostate cancer PC-3, DU145, colon cancer SW620, ovarian cancer IGROV, breast cancer MCF-7, lung cancer A549 FR901228 [44]”
BackgroundInfluentialProlonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma
Weller, M., Gorlia, T., Cairncross, J. G., van den Bent, M. J., Mason, W., Belanger, K., Brandes, A. A., Bogdahn, U., Macdonald, D. R., Forsyth, P., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822f02e1 · Cited by 290 · cited 1×
“A clinical study showed that VPA increased efficacy of radiochemotherapy with temozolomide in glioblastoma patients [176].”
BackgroundNoncoding RNA and Polycomb recruitment
Brockdorff, N. (2013) · RNA · doi:10.1261/rna.037598.112 · Cited by 285
Vrana, J. A., Decker, R. H., Johnson, C. R., Wang, Z., Jarvis, W. D., Richon, V. M., Ehinger, M., Fisher, P. B., & Grant, S. (1999) · Oncogene · doi:10.1038/sj.onc.1203176 · Cited by 284 · cited 6×
“They regulate transcription of pro-apoptotic genes such as Bid (BH3 interacting domain death agonist protein), Bad (Bcl-2 associated agonist of cell death protein) and Bim that activate the intrinsic apoptotic pathway [42,58,63,64].”
BackgroundInfluentialHistone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Bose, P., Dai, Y., & Grant, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.04.004 · Cited by 280 · cited 1×
“, Ku70, flap structure-specific endonuclease 1 (FEN1), Werner syndrome (WRN), ataxia teleangiectasia mutated protein (ATM), mediator of DNA damage checkpoint 1 (MDC1) and DNA-dependent protein kinases (DNA PK) are regulated by acetylation which may be increased by HDAC inhibitors [136].”
BackgroundZhao, Y., Lu, S., Wu, L., Chai, G., Wang, H., Chen, Y., Sun, J., Yu, Y., Zhou, W., Zheng, Q., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2782-2790.2006 · Cited by 277 · cited 2×
“Furthermore, HDAC inhibition increases acetylation of the p53 protein which results in an increase in its half-life [46], thereby improving the interaction with the p21 promoter [47].”
BackgroundRamalingam, S. S., Maitland, M. L., Frankel, P., Argiris, A. E., Koczywas, M., Gitlitz, B., Thomas, S., Espinoza-Delgado, I., Vokes, E. E., Gandara, D. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9094 · Cited by 273 · cited 5×
“SAHA improved effect of carboplatin and paclitaxel in NSCLC [178] and reversed resistance to tamoxifen in estrogen receptor positive breast cancer [179].”
BackgroundInfluentialAnti‐tumor mechanisms of valproate: A novel role for an old drug
Blaheta, R. A., & Cinatl, J. (2002) · Medicinal Research Reviews · doi:10.1002/med.10017 · Cited by 269 · cited 2×
“VPA also affects Wnt signaling that is due to phosphorylation of serine 9 in the glycogen synthase kinase-3β (GSK-3β) [102].”
BackgroundKawasaki, K., Smith, R. S., Hsieh, C.-M., Sun, J., Chao, J., & Liao, J. K. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.16.5726-5737.2003 · Cited by 265
Negative and Positive Regulation of Gene Expression by Mouse Histone Deacetylase 1
Zupkovitz, G., Tischler, J., Posch, M., Sadzak, I., Ramsauer, K., Egger, G., Grausenburger, R., Schweifer, N., Chiocca, S., Decker, T., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.01220-06 · Cited by 263
Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia
Ceccacci, E., & Minucci, S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.36 · Cited by 253
Histone deacetylase inhibitors: Signalling towards p21cip1/waf1
Ocker, M., & Schneider-Stock, R. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.03.001 · Cited by 250 · cited 1×
“The expression of p21 is modulated by protein p53 that interacts with p21 promoter, competing with HDAC1, which decreases transcription of p21 [45].”
BackgroundQiu, L., Burgess, A., Fairlie, D. P., Leonard, H., Parsons, P. G., & Gabrielli, B. G. (2000) · Molecular Biology of the Cell · doi:10.1091/mbc.11.6.2069 · Cited by 249 · cited 1×
“HDAC inhibitors can also inhibit expression of genes coding cyclin D and cyclin A resulting in the absence of activities of the corresponding kinases, CDK2 and CDK4 [44,51].”
BackgroundHistone Acetylation and Chromatin Assembly: A Single Escort, Multiple Dances?
Roth, S. Y., & Allis, C. D. (1996) · Cell · doi:10.1016/s0092-8674(00)81316-1 · Cited by 248
Zhao, Y., Tan, J., Zhuang, L., Jiang, X., Liu, E. T., & Yu, Q. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505585102 · Cited by 246 · cited 4×
“They regulate transcription of pro-apoptotic genes such as Bid (BH3 interacting domain death agonist protein), Bad (Bcl-2 associated agonist of cell death protein) and Bim that activate the intrinsic apoptotic pathway [42,58,63,64].”
BackgroundInfluentialNawrocki, S. T., Carew, J. S., Pino, M. S., Highshaw, R. A., Andtbacka, R. H. I., Dunner, K., Pal, A., Bornmann, W. G., Chiao, P. J., Huang, P., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2961 · Cited by 240 · cited 2×
“6pl, pancreatic epitelium HPDE6-E6E7 Potentiation [151]”
BackgroundBadros, A., Burger, A. M., Philip, S., Niesvizky, R., Kolla, S. S., Goloubeva, O., Harris, C., Zwiebel, J., Wright, J. J., Espinoza-Delgado, I., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2850 · Cited by 231 · cited 1×
“Trials in patients with multiple myeloma demonstrated an increase in SAHA antitumor effects in combination with bortezomib [161,162].”
BackgroundHistone Deacetylase Inhibitors: Current Status and Overview of Recent Clinical Trials
Ma, X., Ezzeldin, H. H., & Diasio, R. B. (2009) · Drugs · doi:10.2165/11315680-000000000-00000 · Cited by 227
HDAC3: taking the SMRT-N-CoRrect road to repression
Karagianni, P., & Wong, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210612 · Cited by 222 · cited 1×
“HDAC complexes can contribute to gene repression through two mechanisms—specific targeting by repressors and the constitutive association with chromatin [24,25].”
BackgroundHistone deacetylase 10 promotes autophagy-mediated cell survival
Oehme, I., Linke, J.-P., Böck, B. C., Milde, T., Lodrini, M., Hartenstein, B., Wiegand, I., Eckert, C., Roth, W., Kool, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1300113110 · Cited by 221 · cited 4×
“HDAC10 induces autophagy-mediated cell survival in neuroblastoma (E(2)-”
BackgroundInfluentialKwon, S. H., Ahn, S. H., Kim, Y. K., Bae, G.-U., Yoon, J. W., Hong, S., Lee, H. Y., Lee, Y.-W., Lee, H.-W., & Han, J.-W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106699200 · Cited by 215 · cited 1×
“Apoptosis death receptor in vitro leukemic cells HL60 apicidin [60]”
BackgroundHistone deacetylase inhibitors and cell death
Zhang, J., & Zhong, Q. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1656-6 · Cited by 214 · cited 1×
“Acetylation of many autophagy-related proteins, such as the product of the autophagy-related genes (ATGs), is regulated by the balance between HATs and HDACs [73].”
BackgroundHistone deacetylase inhibitors in cancer therapy
Rasheed, W. K., Johnstone, R. W., & Prince, H. M. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.5.659 · Cited by 211
Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death
Gammoh, N., Lam, D., Puente, C., Ganley, I., Marks, P. A., & Jiang, X. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204429109 · Cited by 211 · cited 4×
“Several signaling pathways play a role in the induction of autophagy by HDAC inhibitors. mTOR (Mechanistic target of rapamycin) is one of the most important suppressors of autophagy via phosphorylation and inactivation of the ULK1 (Unc 51 like autophagy activating kinase 1) complex which is an upstream component of th…”
BackgroundInfluentialLiu, Y.-L., Yang, P.-M., Shun, C.-T., Wu, M.-S., Weng, J.-R., & Chen, C.-C. (2010) · Autophagy · doi:10.4161/auto.6.8.13365 · Cited by 207 · cited 5×
“Akt/mTOR, ULK1 in vitro liver cancer Hep3B, HepG2, Huh7, mouse embryonic fibroblasts SAHA, TSA, MS275 [80]”
BackgroundInfluentialGriffiths, E. A., & Gore, S. D. (2008) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.11.007 · Cited by 204 · cited 1×
“Inhibitors of DNA methyl transferases azacitidine and decitabine had increased antitumor effects on myelodysplastic syndrome, prostate, ovarian and pancreatic endocrine tumors cells when used with HDAC inhibitors [52,55,142,159,160].”
BackgroundNamdar, M., Perez, G., Ngo, L., & Marks, P. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1013754107 · Cited by 203 · cited 2×
“SAHA, tubacin etoposide, doxorubicin in vitro prostate cancer LNCaP, breast cancer MCF-7, normal human foreskin fibroblast cells Potentiation in ca cells not in fibroblasts [140]”
Histone deacetylases as targets for treatment of multiple diseases
Tang, J., Yan, H., & Zhuang, S. (2013) · Clinical Science · doi:10.1042/cs20120504 · Cited by 200 · cited 1×
“NAD+-dependent homologs 1–7 of the yeast Sir2 proteins (sirtuins) are designed as the class III of HDACs [20].”
BackgroundRössig, L., Li, H., Fisslthaler, B., Urbich, C., Fleming, I., Förstermann, U., Zeiher, A. M., & Dimmeler, S. (2002) · Circulation Research · doi:10.1161/01.res.0000037983.07158.b1 · Cited by 198 · cited 1×
“HDAC inhibitors decrease the stability of eNOS mRNA by binding to the 5′-untranslated region of eNOS mRNA [112].”
BackgroundWitta, S. E., Jotte, R. M., Konduri, K., Neubauer, M. A., Spira, A. I., Ruxer, R. L., Varella-Garcia, M., Bunn, P. A., & Hirsch, F. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.9411 · Cited by 196 · cited 3×
“Phase II study with a combination of erlotinib with entinostat showed prolonged progression-free survival in NSCLC patients harboring high E-cadherin levels, irrespective of the EGFR genotype compared to erlotinib monotherapy, while does not improve the outcome of patients with low E-cadherin [180].”
BackgroundHistone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways
Zhang, J., Ng, S., Wang, J., Zhou, J., Tan, S.-H., Yang, N., Lin, Q., Xia, D., & Shen, H.-M. (2015) · Autophagy · doi:10.1080/15548627.2015.1023981 · Cited by 195 · cited 14×
“FOXO1 in vitro colon cancer HCT116 Tp53 −/− and +/+, mouse embryonic fibroblasts, liver cancer HepG2 TSA [79]”
BackgroundInfluentialValproic acid stimulates proliferation and self-renewal of hematopoietic stem cells.
Bug, G., Gül, H., Schwarz, K., Pfeifer, H., Kampfmann, M., Zheng, X., Beissert, T., Boehrer, S., Hoelzer, D., Ottmann, O. G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3011 · Cited by 195 · cited 2×
“GSK3 β in vitro hematopoetic stem cells VPA [104]”
BackgroundEpigenetic silencing of tumor suppressor genes: Paradigms, puzzles, and potential
Kazanets, A., Shorstova, T., Hilmi, K., Marques, M., & Witcher, M. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.04.001 · Cited by 195 · cited 1×
“Acetylation loosens contact between core nucleosome proteins and DNA, thereby making transcription factor binding sites more accessible, recruitment of bromodomain proteins which recognize acetylated lysine residues on the N-terminal tails of histones and are actively recruited to enhancer and promoter regions [17].”
BackgroundEpigenetic Enhancement of Antigen Processing and Presentation Promotes Immune Recognition of Tumors
Setiadi, A. F., Omilusik, K., David, M. D., Seipp, R. P., Hartikainen, J., Gopaul, R., Choi, K. B., & Jefferies, W. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5270 · Cited by 184 · cited 14×
“We found that VPA and TSA change CYP enzyme expression in neuroblastoma cells [135].”
BackgroundInfluentialGius, D., Cui, H., Bradbury, C. M., Cook, J., Smart, D. K., Zhao, S., Young, L., Brandenburg, S. A., Hu, Y., Bisht, K. S., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.029 · Cited by 181 · cited 3×
“Furthermore, HDAC inhibition increases acetylation of the p53 protein which results in an increase in its half-life [46], thereby improving the interaction with the p21 promoter [47].”
BackgroundEpigenetic control of gene expression: Potential implications for cancer treatment
Perri, F., Longo, F., Giuliano, M., Sabbatino, F., Favia, G., Ionna, F., Addeo, R., Scarpati, G. D. V., Lorenzo, G. D., & Pisconti, S. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.020 · Cited by 177 · cited 1×
“These alterations influence gene transcription including upregulation of several anti-oncogenes and DNA repair genes [2].”
BackgroundHDAC inhibitors and immunotherapy; a double edged sword?
Kroesen, M., Gielen, P. R., Brok, I. C., Armandari, I., Hoogerbrugge, P. M., & Adema, G. J. (2014) · Oncotarget · doi:10.18632/oncotarget.2289 · Cited by 166 · cited 1×
“Inhibition of Class II HDACs enhances number and function of Treg and Class I HDAC inhibitors enhances the functions of NK cells and CD8 T cells [122].”
BackgroundAntileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid
Yang, H., Hoshino, K., Sanchez-Gonzalez, B., Kantarjian, H., & Garcia-Manero, G. (2005) · Leukemia Research · doi:10.1016/j.leukres.2004.11.022 · Cited by 163 · cited 2×
“VPA 5-aza-2′-deoxycytidine in vitro leukemic cells HL-60, MOLT4 Synergism [143]”
BackgroundGarcia-Manero, G., Tambaro, F. P., Bekele, N. B., Yang, H., Ravandi, F., Jabbour, E., Borthakur, G., Kadia, T. M., Konopleva, M. Y., Faderl, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.3265 · Cited by 163 · cited 1×
“The combination of SAHA with idarubicin and cytarabine had synergistic activity that was maximal when SAHA preceded cytarabine and there were responses in all patients with AML with FLT3/ITD mutation, which is otherwise associated with a worse prognosis [164,165].”
BackgroundMahyar-Roemer, M., & Roemer, K. (2001) · Oncogene · doi:10.1038/sj.onc.1204440 · Cited by 162 · cited 2×
“p21 in vitro colon cancer HCT116 + knock out p53−/−, p21−/− sodium butyrate [49]”
BackgroundChen, M., Liao, W. S. ‐., Lü, Z., Bornmann, W. G., Hennessey, V., Washington, M. N., Rosner, G. L., Yu, Y., Ahmed, A. A., & Bast, R. C. (2011) · Cancer · doi:10.1002/cncr.26073 · Cited by 154 · cited 2×
“SAHA, TSA 5-aza-2′-deoxycytidine in vitro ovarian cancer Hey, SKOv3 Synergism [142]”
BackgroundKlisovic, M. I., Maghraby, E. A., Parthun, M. R., Guimond, M., Sklenar, A. R., Whitman, S. P., Chan, K. K. L., Murphy, T., Anon, J., Archer, K. J., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2402776 · Cited by 148 · cited 2×
“Co-treatment of several cancer cells (prostate, pancreatic, lung and AML) with TSA and decitabine synergistically induced apoptosis [52,55,145,146].”
BackgroundHayashi, A., Horiuchi, A., Kikuchi, N., Hayashi, T., Fuseya, C., Suzuki, A., Konishi, I., & Shiozawa, T. (2010) · International Journal of Cancer · doi:10.1002/ijc.25151 · Cited by 145 · cited 1×
“On the contrary, knockdown of HDAC2 has no effect on proliferation and tumorigenicity, or cell migration [15].”
BackgroundWalton, T., Li, G., Seth, R., McArdle, S., Bishop, M. C., & Rees, R. C. (2007) · The Prostate · doi:10.1002/pros.20673 · Cited by 139 · cited 4×
“Co-treatment of several cancer cells (prostate, pancreatic, lung and AML) with TSA and decitabine synergistically induced apoptosis [52,55,145,146].”
BackgroundInfluentialDowdy, S. C., Jiang, S., Zhou, X. C., Hou, X., Jin, F., Podratz, K. C., & Jiang, S.-W. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0209 · Cited by 139 · cited 2×
“There was found that combination of TSA and paclitaxel increases apoptosis induction in endometrial and anaplastic thyroid carcinoma cells [138,157].”
BackgroundEcke, I., Petry, F., Rosenberger, A., Tauber, S., Mönkemeyer, S., Heß, I., Dullin, C., Kimmina, S., Pirngruber, J., Johnsen, S. A., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-0946 · Cited by 138 · cited 2×
“VPA 5-aza-2′-deoxycytidine Ptch knockout mice Potentiation [144]”
BackgroundWoan, K. V., Lienlaf, M., Perez-Villaroel, P., Lee, C., Cheng, F., Knox, T., Woods, D. M., Barrios, K., Powers, J., Sahakian, E., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.04.002 · Cited by 137 · cited 15×
“The subsequent increase in immunogenicity intensifies activation of T cells and the prolonged survival of experimental animals [120,121].”
BackgroundInfluentialChiao, M.-T., Cheng, W.-Y., Yang, Y.-C., Shen, C.-C., & Ko, J.-L. (2013) · Autophagy · doi:10.4161/auto.25664 · Cited by 135 · cited 2×
“Akt/mTOR short term culture glioblastoma cells xenografts in nude mice SAHA [87]”
BackgroundSalvador, M. A., Wicinski, J., Cabaud, O., Toiron, Y., Finetti, P., Josselin, E., Lelièvre, H., Kraus-Berthier, L., Depil, S., Bertucci, F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0877 · Cited by 133 · cited 2×
“Low expression of lncRNA Xist (X inactive specific transcript which plays a major role in the X inactivation process) seems to be a predictor of efficacy of abexinostat in breast cancer cells [97].”
BackgroundStockhausen, M.-T., Sjölund, J., Manetopoulos, C., & Axelson, H. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602309 · Cited by 128 · cited 1×
“For example, VPA has shown to inhibit the invasiveness in bladder cancer but not in prostate cancer cells [40], while it has not induced cell cycle inhibition in some neuroblastoma cell lines such as SH-SY5Y and SK-N-BE [41].”
BackgroundHistone Deacetylase Inhibitors in Cell Pluripotency, Differentiation, and Reprogramming
Kretsovali, A., Hadjimichael, C., & Charmpilas, N. (2012) · Stem Cells International · doi:10.1155/2012/184154 · Cited by 126 · cited 1×
“Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on a type of cancer, on the individual HDAC inhibitor and its dose as well as on some other factors [39].”
BackgroundSuzuki, T., Yokozaki, H., Kuniyasu, H., Hayashi, K., Naka, K., Ono, S., Ishikawa, T., Tahara, E., & Yasui, W. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001215)88:6<992::aid-ijc24>3.0.co;2-9 · Cited by 121 · cited 2×
“p21 in vitro gastric cancer TMK-1, MKN-1, MKN-7, MKN-28, MKN-74, MKN-45, KATO III, HSC-39, oral squamous carcinoma HSC-4, Ho-1-N-1, Ho-1-U-1 TSA [50]”
BackgroundPromoter hypomethylation regulates CD133 expression in human gliomas
Tabu, K., Sasai, K., Kimura, T., Wang, L., Aoyanagi, E., Kohsaka, S., Tanino, M. A., Nishihara, H., & Tanaka, S. (2008) · Cell Research · doi:10.1038/cr.2008.270 · Cited by 121 · cited 1×
“There was described amplification and maintenance of normal human hematopoietic stem cells induced by HDAC inhibitors [128], enhancement of the epithelial–mesenchymal transition of colorectal and breast cancer cells [129,130] and induction of CD133 (a marker of cancer stem cells in some cancers including the brain tum…”
BackgroundEllis, L., Bots, M., Lindemann, R. K., Bolden, J. E., Newbold, A., Cluse, L. A., Scott, C. L., Strasser, A., Atadja, P., Lowe, S. W., et al. (2009) · Blood · doi:10.1182/blood-2008-10-182758 · Cited by 113 · cited 7×
“Panobinostat also underwent phase III clinical trials against CTCL and leukemia in an oral form and showed the positive effect.”
BackgroundInfluentialRyu, C. H., Yoon, W. S., Park, K. Y., Kim, S. M., Lim, J. Y., Woo, J. S., Jeong, C. H., Hou, Y., & Jeun, S.-S. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/987495 · Cited by 113 · cited 3×
“The in vitro experiments and the experiments with mice in vivo showed that the combination of VPA and temozolomide enhanced the apoptotic and autophagic cell death, as well as suppressed the migratory activities in temozolomide-resistant glioblastoma cells that express O-(6)-methylguanine-DNA methyltransferase (MGMT).”
BackgroundInfluentialBlum, K. A., Advani, A., Fernandez, L., Van Der Jagt, R., Brandwein, J., Kambhampati, S., Kassis, J., Davis, M., Bonfils, C., Dubay, M., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07881.x · Cited by 113
Engel, J. A., Jones, A. J., Avery, V. M., Sumanadasa, S. D. M., Ng, S. S., Fairlie, D. P., Skinner‐Adams, T. S., & Andrews, K. T. (2015) · International Journal for Parasitology Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2015.05.004 · Cited by 112 · cited 3×
“Sci. 2017, 18, 1414 10 of 25 HDAC inhibitors have also anti-parasitic activity, e.g., against Plasmodium and Trypanosoma [139].”
InfluentialRudek, M. A., Zhao, M., He, P., Hartke, C., Gilbert, J., Gore, S. D., Carducci, M. A., & Baker, S. D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.450 · Cited by 109 · cited 1×
“Inhibitors of DNA methyl transferases azacitidine and decitabine had increased antitumor effects on myelodysplastic syndrome, prostate, ovarian and pancreatic endocrine tumors cells when used with HDAC inhibitors [52,55,142,159,160].”
BackgroundGameiro, S. R., Malamas, A. S., Tsang, K. Y., Ferrone, S., & Hodge, J. W. (2016) · Oncotarget · doi:10.18632/oncotarget.7180 · Cited by 109 · cited 2×
“After exposure to SAHA or entinostat breast (MDA-MB-231), prostate (LNCaP) and pancreas (AsPC-1) carcinoma cells are more sensitive to T-cell-mediated lysis in vitro [123].”
BackgroundInhibition of histone deacetylase1 induces autophagy
Oh, M., Choi, I.-K., & Kwon, H. J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.03.019 · Cited by 108 · cited 3×
“On the contrary, inhibition or knockdown of HDAC1 in HeLa cells promote formation of autophagic vacuoles [76].”
BackgroundInfluentialValproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study
Scherpereel, A., Berghmans, T., Lafitte, J., Colinet, B., Richez, M., Bonduelle, Y., Meert, A., Dhalluin, X., Leclercq, N., Paesmans, M., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00037310 · Cited by 106 · cited 1×
“VPA with doxorubicin appeared to have the 16% response rate in patients suffering from refractory or recurrent mesothelioma [177].”
BackgroundCheng, F., Lienlaf, M., Wang, H.-W., Perez-Villarroel, P., Lee, C., Woan, K., Rock-Klotz, J., Sahakian, E., Woods, D., Pinilla-Ibarz, J., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302778 · Cited by 106 · cited 2×
“The subsequent increase in immunogenicity intensifies activation of T cells and the prolonged survival of experimental animals [120,121].”
BackgroundHu, Y., Lu, W., Chen, G., Zhang, H., Jia, Y., Wei, Y., Yang, H., Zhang, W., Fiskus, W., Bhalla, K., et al. (2010) · Blood · doi:10.1182/blood-2009-11-256354 · Cited by 102 · cited 2×
“SAHA β-phenylethyl isothiocyanate in vitro leukemia cells HL60, HL60/LR, HL60/C6F, U937, ML1, samples from patients with acute myeloid leukemia Potentiation [147]”
BackgroundHrzenjak, A., Kremser, M., Strohmeier, B., Moinfar, F., Zatloukal, K., & Denk, H. (2008) · The Journal of Pathology · doi:10.1002/path.2434 · Cited by 101 · cited 3×
“C, Kelly, IMR32 siRNA HDAC10 [77] Atg5, 7 & 8 in vitro cervical cancer HeLa, colon cancer HCT116- SIRT1transfected, starvation - [78] FOXO1 in vitro colon cancer HCT116 Tp53 −/− and +/+, mouse embryonic fibroblasts, liver cancer HepG2 TSA [79] Akt/mTOR, ULK1 in vitro liver cancer Hep3B, HepG2, Huh7, mouseembryonic fib…”
BackgroundMichaelis, M., Suhan, T. O., Michaelis, U. R., Beek, K. V., Rothweiler, F., Tausch, L., Werz, O., Eikel, D., Zörnig, M., Nau, H., et al. (2005) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401759 · Cited by 97 · cited 1×
“VPA and TSA decrease the formation of capillary tubes of HUVEC (human vascular endothelial cells), but they do not induce their apoptosis [116].”
BackgroundHighly Compacted Chromatin Formed In Vitro Reflects the Dynamics of Transcription Activation In Vivo
Li, G., Margueron, R., Hu, G., Stokes, D., Wang, Y.-H., & Reinberg, D. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.042 · Cited by 96 · cited 2×
“Histone modifications include H3 and H4 histones lysine deacetylation that leads to chromatin decondensation [1].”
BackgroundEpigenome-Based Personalized Medicine in human Cancer
Yan, W., Herman, J. G., & Guo, M. (2016) · Epigenomics · doi:10.2217/epi.15.84 · Cited by 95 · cited 1×
“HDACs seem to be important for gene expression [5].”
BackgroundCinatl, J. J., Kotchetkov, R., Blaheta, R. A., Driever, P. H., Vogel, J., & Činátl, J. (2002) · International Journal of Oncology · doi:10.3892/ijo.20.1.97 · Cited by 92 · cited 2×
“thrombospondin-1, activin in vitro, neuroblastoma BE(2)-C VPA [114]”
BackgroundCatalano, M. G., Poli, R., Pugliese, M., Fortunati, N., & Boccuzzi, G. (2007) · Endocrine Related Cancer · doi:10.1677/erc-07-0096 · Cited by 91 · cited 2×
“VPA paclitaxel in vitro anaplastic thyroid carcinoma CAL-62, ARO Potentiation [157]”
BackgroundCho, J.-H., Dimri, M., & Dimri, G. P. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.624361 · Cited by 88 · cited 2×
“Treatment of breast cancer cells and normal human fibroblasts with a combination of sodium butyrate and panobinostat increased the expression of miR-31 which induces cellular senescence via inhibition of BIM1 (Bisindolylmaleimide-based protein kinase C inhibitor 1) [89].”
BackgroundMiR-129-5p is required for histone deacetylase inhibitor-induced cell death in thyroid cancer cells
Brest, P., Lassalle, S., Hofman, V., Bordone, O., Tanga, V., Bonnetaud, C., Moreilhon, C., Rios, G., Santini, J., Barbry, P., et al. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0257 · Cited by 88 · cited 3×
“Effect on non-coding RNA miR-129-5p→ GALNT1 & SOX4 in vitro thyroid carcinoma BCPAP, TPC-1, 8505C, CAL62 TSA, SAHA [88]”
BackgroundHistone deacetylase 1 enhances microRNA processing via deacetylation of DGCR8
Wada, T., Kikuchi, J., & Furukawa, Y. (2012) · EMBO Reports · doi:10.1038/embor.2011.247 · Cited by 87 · cited 7×
“Drosha/DGCR8 in vitro 293FT embryonal kidney cells HDAC1 transfected / [91]”
BackgroundInfluentialPark, M. A., Reinehr, R., Häussinger, D., Voelkel‐Johnson, C., Öğretmen, B., Yacoub, A., Grant, S., & Dent, P. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0274 · Cited by 87 · cited 1×
“Some studies also show that SAHA cause autophagy by ROS production in leukemic and hepatocellular carcinoma derived cells [84,86].”
BackgroundTherapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
Miller, C. P., Singh, M. M., Rivera-Del Valle, N., Manton, C. A., & Chandra, J. (2011) · BioMed Research International · doi:10.1155/2011/514261 · Cited by 86 · cited 3×
“In addition, tranylcypromine (monoamine oxidase inhibitor) and SAHA showed synergistic enhancement of apoptosis in glioblastoma cells [58].”
BackgroundShulak, L., Beljanski, V., Chiang, C., Dutta, S. M., van Grevenynghe, J., Belgnaoui, S. M., Nguyên, T. L.-A., Lenardo, T. Z. D., Semmes, O. J., Lin, R., et al. (2013) · Journal of Virology · doi:10.1128/jvi.03406-13 · Cited by 84 · cited 3×
“C, Kelly, IMR32 siRNA HDAC10 [77] Atg5, 7 & 8 in vitro cervical cancer HeLa, colon cancer HCT116- SIRT1transfected, starvation - [78] FOXO1 in vitro colon cancer HCT116 Tp53 −/− and +/+, mouse embryonic fibroblasts, liver cancer HepG2 TSA [79] Akt/mTOR, ULK1 in vitro liver cancer Hep3B, HepG2, Huh7, mouseembryonic fib…”
BackgroundLi, J., Liu, R., Lei, Y., Wang, K., Lau, Q. C., Xie, N., Zhou, S., Nie, C., Chen, L., Wei, Y., et al. (2010) · Autophagy · doi:10.4161/auto.6.6.12397 · Cited by 83 · cited 5×
“Several signaling pathways play a role in the induction of autophagy by HDAC inhibitors. mTOR (Mechanistic target of rapamycin) is one of the most important suppressors of autophagy via phosphorylation and inactivation of the ULK1 (Unc 51 like autophagy activating kinase 1) complex which is an upstream component of th…”
BackgroundInfluentialAsghari, V., Wang, J. F., Reiach, J. S., & Young, L. T. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(98)00107-7 · Cited by 82 · cited 3×
“HDAC inhibitors were found to increase DNA binding and transactivation activity of AP-1 transcription factor via ERK activation, increase expression of c-Jun (Jun activation domain binding protein) and induce its phosphorylation in SH-SY5Y neuroblastoma cells [65,98].”
BackgroundLin, K.-T., Wang, Y.-W., Chen, C.-T., Ho, C.-M., Su, W.-H., & Jou, Y.-S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0633 · Cited by 80 · cited 1×
“found that HDAC inhibition resulted in the development of metastatic phenotype including increasing of matrix metalloproteinases (MMPs) expression in some cancer cell lines (liver (SNU-398, Huh6, HepG2, Hep3B, Huh7, PLC5, HCC36, TONG, HA59T, Sk-hep-1, HA22T, and Malhavu), lung (H358, H1437, H661, H226Br, H1299, CL1-3,…”
BackgroundGeneration of pluripotent stem cells without the use of genetic material
Higuchi, A., Ling, Q., Kumar, S. S., Munusamy, M. A., Alarfaj, A. A., Chang, Y., Kao, S.-H., Lin, K.-C., Wang, H.-C., & Umezawa, A. (2014) · Laboratory Investigation · doi:10.1038/labinvest.2014.132 · Cited by 78 · cited 1×
“Therefore, several inhibitors of epigenetic-modifying enzymes including HDAC are able to reprogram somatic cells into the pluripotent stem cells by modifying a chromatin structure and making it more permissive to transcription factors [127].”
BackgroundChai, G., Li, L., Zhou, W., Wu, L., Zhao, Y., Wang, D., Lu, S., Yu, Y., Wang, H., McNutt, M. A., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002445 · Cited by 76 · cited 2×
“TSA 5-aza-2′-deoxycytidine in vitro lung cancer A549, H719 Synergism [146]”
BackgroundStiborová, M., Eckschlager, T., Poljaková, J., Hraběta, J., Adam, V., Kizek, R., & Frei, E. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712802884286 · Cited by 76 · cited 2×
“, doxorubicin, epirubicin, etoposid, CDDP, melphalan, and temozolomide) and ionizing radiation in many cancer cell lines (reviewed in [37]).”
BackgroundSelf-citationTakashina, T., Kinoshita, I., Kikuchi, J., Shimizu, Y., Sakakibara‐Konishi, J., Oizumi, S., Nishimura, M., & Dosaka‐Akita, H. (2016) · Cancer Science · doi:10.1111/cas.12957 · Cited by 76 · cited 2×
“The co-treatment by EZH and HDAC inhibitors induced accumulation of p27Kip (Cyclin dependent kinase inhibitor p27) and a decrease in cyclin A, suppressed EGFR signaling, both in EGFR-wild-type and mutant NSCLC cells [149].”
BackgroundMethodModulation of TRAIL-Induced Apoptosis by HDAC Inhibitors
Fulda, S. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908783769355 · Cited by 75
Greve, G., Schiffmann, I., Pfeifer, D., Pantić, M., Schüler, J. B., & Lübbert, M. (2015) · BMC Cancer · doi:10.1186/s12885-015-1967-5 · Cited by 75 · cited 2×
“Panobinostat erlotinib in vitro lung cancer HCC827, A549, NCI-H460 (EGFR wild type and mutant) Synergism/Potentiation [148]”
BackgroundThe Role of NAD+ Dependent Histone Deacetylases (sirtuins) in Ageing
Trapp, J. (2006) · Current Drug Targets · doi:10.2174/1389450110607011553 · Cited by 65 · cited 1×
“The further HDAC family is NAD+-dependent, being capable of forming O-acetyl ADP ribose and nicotinamide as a result of the acetyl transfer [22].”
BackgroundCieslik, K., Abrams, C. S., & Wu, K. K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005305200 · Cited by 65 · cited 1×
“Although it is not yet clear how HDAC inhibitors affect ERK, it is supposed that they can induce synthesis of a still unknown factor that activate the ERK signaling pathway [65] or is incorporated into phospholipid molecules that activates ERK via the phosphatidylinositol 3-kinase (PI-3K)/Janus kinase 2 (JAK 2)/MEK-1-…”
BackgroundMani, S., Shen, Y., Schaefer, J., & Meiri, K. F. (2001) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0931 · Cited by 65 · cited 1×
“, in SH-SY5Y neuroblastoma cells or immature cortical neuroblasts in GAP-43−/− mice [65,101].”
BackgroundAfifi, S., Michael, A., Azimi, M., Rodríguez, M., Lendvai, N. K., & Landgren, O. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1671 · Cited by 65 · cited 1×
“The most common toxicities of those HDAC inhibitors, which are not the class-specific and have been observed in all their types, are thrombocytopenia, neutropenia, diarrhea, nausea, vomiting and fatigue [163].”
BackgroundYang, H., Zhong, Y., Xie, H., Lai, X., Xu, M., Nie, Y., Liu, S., & Wan, Y. Y. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.04.020 · Cited by 61 · cited 13×
“We found that VPA and TSA change CYP enzyme expression in neuroblastoma cells [135].”
BackgroundInfluentialShao, L., Diccianni, M. B., Tanaka, T. S., Gribi, R., Yu, A. L.-T., Pullen, J., Camitta, B. M., & Yu, A. L.-T. (2001) · PubMed · Cited by 60
Bassa, B. V., Roh, D. D., Vaziri, N. D., Kirschenbaum, M. A., & Kamanna, V. S. (1999) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.1999.277.3.f328 · Cited by 57 · cited 1×
“Although it is not yet clear how HDAC inhibitors affect ERK, it is supposed that they can induce synthesis of a still unknown factor that activate the ERK signaling pathway [65] or is incorporated into phospholipid molecules that activates ERK via the phosphatidylinositol 3-kinase (PI-3K)/Janus kinase 2 (JAK 2)/MEK-1-…”
BackgroundGao, S., Mobley, A. K., Miller, C. P., Boklan, J., & Chandra, J. (2007) · Leukemia Research · doi:10.1016/j.leukres.2007.09.007 · Cited by 55 · cited 10×
“Besides, these effects on gene expression, the HDAC inhibitors increase amounts of reactive oxygen species (ROS) that can induce apoptosis in leukemic cells (Jurkat, ML-1, U937, HL-60, K-562, CEM-CCRF and its doxorubicin selected P-glycoprotein overexpressing subline and FDC-P1 and sublines overexpressing Bid, Bcl-2 a…”
BackgroundInfluentialValproic Acid Inhibits Invasiveness in Bladder Cancer but Not in Prostate Cancer Cells
Chen, C., Sung, J., Cohen, M. J., Chowdhury, W. H., Sachs, M. D., Li, Y., Lakshmanan, Y., Yung, B. Y., Lupold, S. E., & Rodríguez, R. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.106658 · Cited by 53 · cited 1×
“For example, VPA has shown to inhibit the invasiveness in bladder cancer but not in prostate cancer cells [40], while it has not induced cell cycle inhibition in some neuroblastoma cell lines such as SH-SY5Y and SK-N-BE [41].”
BackgroundMyc Induces miRNA-Mediated Apoptosis in Response to HDAC Inhibition in Hematologic Malignancies
Adams, C. M., Hiebert, S. W., & Eischen, C. M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1751 · Cited by 53 · cited 2×
“miR-31→BMI1 in vitro breast cancer MDA-MB-231, MCF7, 293T, embryonal lung fibroblasts sodium butyrate, panobiostat [89] miR-15 & let-7→Myc in vitro and mice xenografts leukemic cells/lymphoma Daudi, Ramos, Raji, Su-DHL-6, NIH3T3, P493-6 RGFP966, depsipetide [90]”
BackgroundWu, S., Luo, Z., Yu, P.-J., Xie, H., & He, Y.-W. (2016) · Biological Chemistry · doi:10.1515/hsz-2015-0215 · Cited by 51 · cited 2×
“There was described amplification and maintenance of normal human hematopoietic stem cells induced by HDAC inhibitors [128], enhancement of the epithelial–mesenchymal transition of colorectal and breast cancer cells [129,130] and induction of CD133 (a marker of cancer stem cells in some cancers including the brain tum…”
BackgroundBhaskara, S. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1042634 · Cited by 50 · cited 1×
“HDAC1 and 2 inhibition decreases the DNA repair processes mediated by BAL-associated protein (BBAP) which protects cells against DNA-damaging agents [137].”
BackgroundLuchenko, V. L., Salcido, C. D., Zhang, Y., Agama, K., Komlódi-Pásztor, E., Murphy, R. F., Giaccone, G., Pommier, Y. G., Bates, S. E., & Varticovski, L. (2011) · Cell Cycle · doi:10.4161/cc.10.18.17190 · Cited by 49 · cited 2×
“[155] indicated that DNA relaxation is not required for the synergy of belinostat and romidepsin with CDDP and VP-16 in small cell lung cancer cells.”
BackgroundValente, S., & Mai, A. (2014) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2014.877446 · Cited by 49
Feng, J.-T., Junhua, C., Li, J., Zhao, R., Zhu, C., Wang, Z., Xie, J., & Tang, W. (2015) · Cell Adhesion & Migration · doi:10.1080/19336918.2015.1112486 · Cited by 48 · cited 2×
“There was described amplification and maintenance of normal human hematopoietic stem cells induced by HDAC inhibitors [128], enhancement of the epithelial–mesenchymal transition of colorectal and breast cancer cells [129,130] and induction of CD133 (a marker of cancer stem cells in some cancers including the brain tum…”
BackgroundGroh, T., Hraběta, J., KHALIL, M. A., Doktorová, H., Eckschlager, T., & Stiborová, M. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2996 · Cited by 47 · cited 4×
“VPA cisplatin, etoposide in vitro neuroblastoma cell UKF-NB-4 Potentiation-schedule dependent [154]”
BackgroundResultInfluentialSelf-citationGhobrial, I. M., Campigotto, F., Murphy, T. J., Boswell, E. N., Banwait, R., Azab, F., Chuma, S., Kunsman, J., Donovan, A., Masood, F., et al. (2013) · Blood · doi:10.1182/blood-2012-06-439307 · Cited by 47 · cited 1×
“The clinical phase II study proved that panobinostat is effective in relapsed/refractory Waldenstrom macroglobulinemia [170].”
BackgroundCecconi, D., Donadelli, M., Pozza, E. D., Rinalducci, S., Zolla, L., Scupoli, M. T., Righetti, P. G., Scarpa, A., & Palmieri, M. (2009) · PROTEOMICS · doi:10.1002/pmic.200701089 · Cited by 43 · cited 5×
“RUNX3 in vitro pancreatic endocrine tumors- insulinoma CM, carcinoid BON, somatostatinoma QCP-1 TSA [52]”
BackgroundInfluentialAnalysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors
Kortenhorst, M. S. Q., Wissing, M. D., Rodríguez, R., Kachhap, S. K., Jans, J. J. M., van der Groep, P., Verheul, H. M. W., Gupta, A. K., Aiyetan, P., van der Wall, E., et al. (2013) · Epigenetics · doi:10.4161/epi.25574 · Cited by 37 · cited 3×
“MHC genes in vitro prostate cancer PCa and DU-145 VPA [126]”
BackgroundFröhlich, L. F., Mrakovcic, M., Smole, C., & Zatloukal, K. (2016) · Cancer Cell International · doi:10.1186/s12935-016-0343-0 · Cited by 35 · cited 3×
“C, Kelly, IMR32 siRNA HDAC10 [77] Atg5, 7 & 8 in vitro cervical cancer HeLa, colon cancer HCT116- SIRT1transfected, starvation - [78] FOXO1 in vitro colon cancer HCT116 Tp53 −/− and +/+, mouse embryonic fibroblasts, liver cancer HepG2 TSA [79] Akt/mTOR, ULK1 in vitro liver cancer Hep3B, HepG2, Huh7, mouseembryonic fib…”
BackgroundTargeting epigenetic changes in acute myeloid leukemia.
Blum, W. G., & Marcucci, G. (2005) · PubMed · Cited by 33
Mazumder, A., Vesole, D. H., & Jagannath, S. (2010) · Clinical Lymphoma Myeloma & Leukemia · doi:10.3816/clml.2010.n.022 · Cited by 32
Valproic acid overcomes hypoxia-induced resistance to apoptosis
Cipro, Š., Hřebačková, J., Hraběta, J., Poljaková, J., & Eckschlager, T. (2011) · Oncology Reports · doi:10.3892/or.2011.1577 · Cited by 31 · cited 2×
“We found that VPA induces apoptosis more effectively under hypoxic conditions and overcomes hypoxia-induced resistance to cisplatin (CDDP) in high risk neuroblastoma derived cells UKF-NB-3 and CDDP resistant subline [71] probably by induction of HIF-1α degradation [72].”
BackgroundMethodSelf-citationZhu, J., Wan, H., Xue, C., Jiang, T., Qian, C., & Zhang, Y. (2013) · Brain Research · doi:10.1016/j.brainres.2013.04.061 · Cited by 27 · cited 1×
“The experimental in vitro study showed that HDAC3 promoted self-renewal of glioma stem cells and those experimental results were proved also by the studies utilizing the tumor samples [132].”
ResultHřebačková, J., Poljaková, J., Eckschlager, T., Hraběta, J., Procházka, P., Smutný, S., & Stiborová, M. (2009) · Interdisciplinary Toxicology · doi:10.2478/v10102-009-0019-x · Cited by 26 · cited 1×
“We found that VPA and TSA change CYP enzyme expression in neuroblastoma cells [135].”
BackgroundSelf-citationKhalil, M. A., Hraběta, J., Groh, T., Procházka, P., Doktorová, H., & Eckschlager, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162916 · Cited by 26 · cited 3×
“Furthermore, assumption about the role of some HDAC inhibitors as inducers of cancer stem cells [133,134] or about the phenomenon that HDAC inhibition may enhance the epithelial–mesenchymal transition of cancer cells [129,130] needs further studies.”
BackgroundSelf-citationBurba, I., Colombo, G. I., Staszewsky, L. I., Simone, M. C. D., Devanna, P., Nanni, S., Avitabile, D., Molla, F., Cosentino, S., Russo, I., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022158 · Cited by 25 · cited 1×
“There was described amplification and maintenance of normal human hematopoietic stem cells induced by HDAC inhibitors [128], enhancement of the epithelial–mesenchymal transition of colorectal and breast cancer cells [129,130] and induction of CD133 (a marker of cancer stem cells in some cancers including the brain tum…”
BackgroundValproic Acid Alters Angiogenic and Trophic Gene Expression in Human Prostate Cancer Models
Chelluri, R. R., Caza, T. N., Woodford, M. R., Reeder, J. E., Bratslavsky, G., & Byler, T. K. (2016) · Anticancer Research · doi:10.21873/anticanres.11077 · Cited by 17 · cited 1×
“Expression array showed that in prostate cancer cells VPA induces the up-regulation of TSP1 (Thrombospondin-1), multiple TIMP (Tissue inhibitor of metalloproteinase) isoforms and TGFβ (Transforming growth factor β), while expression of IGF1 (Insulin like growth factor 1) and VEGF is decreased [115].”
BackgroundNew Strategies in Acute Myeloid Leukemia: Redefining Prognostic Markers to Guide Therapy
Khan, I., Altman, J. K., & Licht, J. D. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0313 · Cited by 16 · cited 1×
“The combination of SAHA with idarubicin and cytarabine had synergistic activity that was maximal when SAHA preceded cytarabine and there were responses in all patients with AML with FLT3/ITD mutation, which is otherwise associated with a worse prognosis [164,165].”
BackgroundDoes valproic acid affect tumor growth and improve survival in glioblastomas?
Rudà, R., Pellerino, A., & Soffietti, R. (2016) · CNS Oncology · doi:10.2217/cns-2016-0004 · Cited by 13
Sabbatino, F., Schwab, J. H., Ferrone, S., & Ferrone, C. R. (2013) · PubMed · Cited by 12
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
“Sirtinol, cambinol, and EX-527 are specific SIRT1 and SIRT2 inhibitors (Ceccacci and Minucci, 2016; Eckschlager et al., 2017).”
BackgroundThirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
“HDACi have pleiotropic cellular effects (Figure 2) and induce the expression of pro-apoptotic genes/proteins, cause cellular differentiation and/or cell cycle arrest (13, 15, 19, 25, 26).”
BackgroundToward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Metadata
- Authors
- Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J.
- Affiliations
- Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84/1, Prague 5 CZ-150 06, Czech Republic
- Charles University (CZ)
- Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030/8, Prague 2 CZ-128 43, Czech Republic
- ORCID
- Stiborova, Marie
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-07-01
- Volume
- 18
- Issue
- 7
- Pages
- 1414
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5535906
- OpenAlex
- W2724336500
- Cited by
- 1,206
- References
- 184
- Citations by year
- 2026: 64 · 2025: 107 · 2024: 107 · 2023: 140 · 2022: 164 · 2021: 195 · 2020: 170 · 2019: 164 · 2018: 85 · 2017: 9
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministerstvo Zdravotnictví Ceské Republiky (00064203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, epigenetic regulation, histone acetylation, histone acetyltransferase, differentiation therapy, angiogenesis, immune response, vorinostat, romidepsin, belinostat, panobinostat, T-cell lymphoma, multiple myeloma, epigenetic therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Signal Transduction, Gene Expression Regulation, Neoplastic, Apoptosis, Angiogenesis Inhibitors, Epigenesis, Genetic, Histone Deacetylase Inhibitors, Immunomodulation, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
